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mechanisms by which the hexanucleotide repeat expan-
sion causes disease are unclear and both gain- and loss-of- 
function mechanisms may play a role. Our data support 
a gain-of-function mechanism as pure homozygous loss 
of function would be expected to lead to a more severe, 
or completely different clinical phenotype to the one 
described here, which falls within the usual range. Our 
findings have implications for genetic counselling, high-
lighting the need to use genetic tests that distinguish 
C9orf72 homozygosity.
Keywords C9orf72 · ALS · FTD
Introduction
Frontotemporal dementia (FTD) is the most common 
form of early-onset dementia, second only to Alzhei-
mer’s disease, and is characterised clinically by changes 
Abstract An expanded hexanucleotide repeat in the 
C9orf72 gene is the most common genetic cause of 
frontotemporal dementia and amyotrophic lateral scle-
rosis (c9FTD/ALS). We now report the first description 
of a homozygous patient and compare it to a series of 
heterozygous cases. The patient developed early-onset 
frontotemporal dementia without additional features. 
Neuropathological analysis showed c9FTD/ALS char-
acteristics, with abundant p62-positive inclusions in the 
frontal and temporal cortices, hippocampus and cerebel-
lum, as well as less abundant TDP-43-positive inclu-
sions. Overall, the clinical and pathological features were 
severe, but did not fall outside the usual disease spectrum. 
Quantification of C9orf72 transcript levels in post-mortem 
brain demonstrated expression of all known C9orf72 
transcript variants, but at a reduced level. The pathogenic 
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in personality or language impairment and pathologically 
by the progressive degeneration of the frontal and ante-
rior temporal lobes [21, 24]. FTD shares numerous simi-
larities at the genetic and neuropathological level with 
amyotrophic lateral sclerosis (ALS), a devastating neuro-
degenerative disorder in which the loss of motor neurons 
in brain and spinal cord causes progressive weakness 
and paralysis, ultimately leading to death from respira-
tory failure [12]. ALS and FTD can co-occur, and they 
have been proposed to be part of the same spectrum of 
disease [17].
An expanded hexanucleotide repeat in the C9orf72 gene 
has been identified recently as the most common known 
genetic cause of both FTD and ALS [9, 20, 25]. Whilst 
<33 hexanucleotide repeats occur in the healthy general 
population, with just 2 repeats being the most common 
form, C9orf72 ALS/FTD cases carry 800–4,400 repeats 
[5]. C9orf72 positive FTD (c9FTD) cases may show clini-
cally typical FTD features and have been described to most 
commonly present with behavioural variant frontotemporal 
dementia, often with prominent psychiatric and amnestic 
symptoms [19].
Pathologically, c9FTD patients have unique character-
istics, including p62-positive neuronal cytoplasmic inclu-
sions (NCIs) in cerebellar and dentate fascia granule cells 
and pyramidal neurons of the hippocampus [19, 23, 26]. 
The pathogenic mechanisms by which the hexanucleotide 
repeat expansion causes disease are unclear and both gain- 
and loss-of-function mechanisms have been proposed to 
play a role [3, 9, 10, 22]. Here, we present a case of FTD 
with a homozygous C9orf72 hexanucleotide repeat expan-
sion and compare with heterozygous cases. Clinical fea-
tures, neuropathology and expression data that we describe 
below carry important implications for disease pathogen-
esis and genetic counselling.
Materials and methods
DNA extraction and genotyping
Genomic DNA was extracted from peripheral blood using 
the Nucleon BACC2 DNA extraction kit (RPN8502) fol-
lowing the supplied protocol. DNA concentrations were 
determined using a Nanodrop ND-1000 spectrophotometer, 
and adjusted to a working concentration of 20 ng/μl TE 
buffer.
Rs3849942 genotyping: The surrogate marker 
rs3849942, defining the haplotypes at risk of expan-
sion, was genotyped by allelic discrimination using the 5′ 
nuclease assay in conjunction with Minor Groove Binding 
(MGB) probes. The custom-designed assay was performed 
on the SDS7500 Fast Real Time PCR system (ABI) and 
genotyping calls were made using software v2.0.6.
Hexanucleotide repeat number assessment
Hexanucleotide repeat number was assessed by repeat 
primed PCR and carried out as previously described [19]. 
Fragment length analysis was undertaken on an ABI 
3730xl automated sequencer. Analysis of repeat primed 
PCR (rpPCR) electrophoretograms was performed using 
Peak Scanner v1.0 (ABI). In addition, repeat number was 
assessed by fluorescent labelled PCR followed by fragment 
length analysis on an Applied Biosystems (ABI) 3730xl 
automated sequencer as previously described [19].
Microsatellite analysis
Microsatellite analysis was performed using ten markers 
spanning approximately 13.1 Mb of genomic DNA cen-
tred on the C9orf72 gene. PCR amplicons were generated 
using fluorescently end-labelled primers for microsatellite 
markers D9S1814(VIC), D9S976(FAM), D9S171(NED), 
D9S1121(VIC), D9S169(FAM), D9S263(HEX), D9S270 
(FAM), D9S104(FAM), D9S147E(NED) and D9S761 
(FAM). DNA products were electrophoresed on an ABI 
3730xl automated sequencer. Data were analysed using 
ABI GeneMapper software v4.0 [Applied Biosystems 
(ABI)].
Southern blotting
Adaptation of standard blotting methods included the prob-
ing of AluI/DdeI digested genomic DNA with an oligonu-
cleotide hybridisation probe from Eurofins MWG Operon 
(Germany) that comprised five hexanucleotide repeats 
(GGGGCC)5 labelled 3′ and 5′ with digoxigenin (DIG). 
Further methods followed the DIG Application Manual 
[Roche Applied Science (RAS)], except for the supplemen-
tation of DIG Easy Hyb buffer with 100 μg/ml denatured 
fragmented salmon sperm DNA. Detection was carried 
out as recommended in the DIG Application Manual using 
CSPD ready-to-use (RAS) as chemiluminescent substrate 
visualised on fluorescent detection film (RAS). Hexanucle-
otide repeat number was estimated by visual interpolation 
using a plot of log10 base pair number against migration 
distance which was created in Excel (Microsoft) and sub-
traction of the wild-type allele fragment size (199 bp). Full 
methods have been previously reported [5].
For single probe Southern hybridisation, 5 μg genomic 
DNA were digested with EcoRI. The Roche DIG label-
ling and detection system was used with a 1 kb C9orf72 
genomic DNA specific probe.
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Pathological analysis
Analysis was undertaken according to the Queen Square 
Brain Bank protocol [16]. p62 (1:200, BD Transduction 
Laboratories), TDP-43 (amino acids 1-261, Abnova, 1:800), 
C9RANT [3] and ubiquilin-2 [6] were analysed. Using a 
semi-quantitative approach, the frequency of p62-positive 
neuronal cytoplasmic inclusions was compared with TDP-
43-positive inclusions in the reported regions of the frontal 
cortex, temporal cortex, hippocampus and cerebellum.
Semi-quantitative analysis of p62 and TDP-43-positive 
lesions was performed using a five-tiered semi-quantitative 
grading scale. The scoring of the pathological lesions was 
as follows: ‘0’ for the absence of p62-positive neuronal 
cytoplasmic inclusions (NCIs) and neuronal intranuclear 
inclusions (NIIs); ‘+’ for 1–5 inclusions present in an aver-
age of at least five microscopic fields using a 20× objec-
tive; ‘++’ for 6–10; ‘+++’ for between 11 and 20 inclu-
sions; ‘++++’ for >20 lesions.
RNA extraction and transcription analysis
RNA extraction was performed using the miRNeasy 
Kit (Qiagen) and RNA quality was evaluated using the 
Agilent 2100 Bioanalyzer. Reverse transcription was 
performed using the QuantiTect kit (Qiagen) and real-
time quantitative RT-PCR (qPCR) was performed using 
Taqman probes according to manufacturer’s instructions 
(Applied Biosytems Primers and probes were designed in 
order to specifically detect the V1, V2 and V3 C9orf72 
isoforms (Supplementary table 1). Dilution curve experi-
ments using the V1 and V3 C9orf72 primers vs beta-
actin showed comparable efficiencies. Reactions were 
performed in triplicate and gene expression values were 
normalised using the housekeeping genes ACTB and 
GAPDH. Relative quantification of gene expression was 
calculated via the comparative threshold cycle (ddCt) 
method. Regression analysis was performed by plotting 
the expression values vs the number of mutated alleles 
using Graphpad Prism v5.03.
Results
Patient report
A 45-year-old man originally from Turkey presented to a 
cognitive disorders clinic with a 2-year history of change 
in behaviour and cognitive impairment. He had become 
apathetic with increasing irritability and his behaviour was 
described as having become increasingly childish. Over 
the following 2 years prior to presentation he rapidly dete-
riorated such that when assessed he was severely apathetic 
and speech output was minimal. He was unable to follow 
more than simple commands and did not recognise his fam-
ily. He required assistance with dressing and eating and 
was doubly incontinent.
The proband’s mother and father were first cousins, their 
fathers being brothers. Both parents developed an early-
onset dementia, and a number of other family members 
developed dementia, with an autosomal dominant compat-
ible transmission (Fig. 1a).
Neurological examination revealed an MMSE of 9 and 
relatively global cognitive impairment with formal neu-
ropsychometric testing. The proband was echolalic. Dur-
ing testing he was perseverative and disinhibited. He had 
a mild extrapyramidal syndrome with bilateral limb brad-
ykinesia and rigidity with stimulus-sensitive myoclonus 
and limb apraxia. He had symmetrically brisk reflexes with 
downgoing plantar responses. Limb power and co-ordina-
tion were normal with no wasting or fasciculations—EMG 
was not performed. He continued to progress rapidly with 
increasingly disinhibited and aggressive behaviour and died 
less than a year later.
Cerebro-spinal fluid (CSF) examination revealed tau lev-
els of 171 pg/ml (0–320) and Aβ1-42 of 180 pg/ml (220–
2,000). Oligoclonal bands were negative and CSF was 
acellular. EEG was unremarkable. A brain MRI showed 
generalised atrophy with frontal and medial temporal pre-
dominance without any clear asymmetry (Fig. 1b).
Fig. 1  Family history and clinical features. a Pedigree of the family. 
Arrow identifies the proband; age of onset is indicated below affected 
individuals (filled symbols). b Coronal brain MRI T1-weighted scan, 
showing bilateral widespread atrophy
404 Acta Neuropathol (2013) 126:401–409
1 3
Genetic analysis
The patient’s DNA was sequenced to screen the PRNP, 
APP, PSEN1, PSEN2, GRN, and MAPT, genes, all of which 
were negative for mutations, and for C9orf72 hexanucleo-
tide repeat number by repeat primed PCR, which showed 
a minimum of 40 repeats and a positive expansion pattern 
(Fig. 2a). The presence of a large expansion was confirmed 
by Southern blotting on DNA from peripheral lympho-
cytes using a GGGGCC5 oligonucleotide probe that targets 
the expansion [5], revealing a maximum of 3,067 repeats, 
minimum 830 (mode of 2,297 repeats, Fig. 2c). Assessment 
of repeat number of the presumed non-expanded allele by 
fluorescent PCR appeared to fail repeatedly, not reveal-
ing any bands despite test sensitivity proven from 2 to 32 
repeats [5]. Results of haplotype analysis using 10 highly 
polymorphic microsatellite markers spanning 13.1 Mb 
centred on C9orf72 showed homozygosity at all markers 
and genotyping of rs3849942 demonstrated homozygo-
sity for the adenosine nucleotide at this polymorphic site, 
typically linked with expanded alleles (Fig. 2b). These 
results pointed to the presence of a homozygous C9orf72 
Fig. 2  Presence of a homozy-
gous hexanucleotide expan-
sion in C9orf72. a Results of 
repeat primed PCR for C9orf72 
expansion demonstrating the 
saw-tooth pattern, typical of 
the pathological expansion. 
Repeats are measurable up to 40 
hexanucleotide repeats. The size 
of fluorescently labelled DNA 
amplicons is shown in base 
pairs (bp) against the expected 
asymptotic decay in fluores-
cence measured in arbitrary 
units. The GS500 size standard 
can also be seen with red peaks 
at 300, 340, 350, 400, 450, 490 
and 500 bp. b Results of genetic 
analysis of the proband that 
demonstrate homozygosity at all 
microsatellite marker positions 
and at rs3849942. Positions of 
markers are given in megabases 
relative to chromosome and 
C9orf72 position. c Southern 
blot analysis on blood-derived 
DNA using a probe directed 
to the hexanucleotide repeat 
(GGGGCC)5 shows the pres-
ence of an expansion in the 
proband (C9 hom). The expan-
sion is calculated to have a 
maximum of 3,067, a minimum 
830 and mode of 2,297 repeats 
and is indistinguishable from 
a C9orf72 heterozygous case 
(C9 het). d Southern blot 
analysis on blood and brain 
(asterisk) derived DNA using a 
single-copy probe detecting the 
sequence adjacent to the repeat. 
The normal allele runs as an 
8-kb band and is detectable in 
controls and C9orf72 expan-
sion heterozygous cases, but is 
absent in the proband (C9 hom)
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expansion and indeed, Southern blotting performed using 
a single-copy probe detecting the sequence adjacent to the 
repeat showed lack of a normal allele, confirming homozy-
gosity of the C9orf72 expansion (Fig. 2d).
Neuropathology analysis of C9orf72 homozygous  
and heterozygous cases
Neuropathological examination revealed a reduced brain 
weight (1,015 g), with frontoparietal atrophy. The corpus 
callosum, caudate, globus pallidus, thalamus, amygdala 
and hippocampus were all reduced in bulk. There was also 
pallor of the substantia nigra and locus coeruleus. However, 
the cerebellar white matter and dentate nucleus appeared 
normal. Microscopic assessment identified morphologi-
cal features consistent with FTLD-TDP type A including 
TDP-43-positive neuronal cytoplasmic inclusions (NCIs), 
neuronal intranuclear inclusions (NIIs) and short neuritic 
threads. TDP-43-positive neurites and oligodendroglial 
inclusions were found in the deep white matter of the fron-
tal cortex (Supplementary figure 1). No spinal cord was 
available for study; however, motor neurons of the 7th and 
12th nerve nuclei were available for pathological assess-
ment and showed no TDP-43 or p62-positive inclusions. 
There was no evidence of hippocampal sclerosis, whilst 
AT8 immunohistochemistry showed neuropil threads and 
neurofibrillary tangles in the transentorhinal and entorhinal 
cortices in keeping with Braak and Braak stage II. p62-pos-
itive NCIs were evident not only in the hippocampus and 
cerebellum, a consistent feature of C9orf72 expansion 
cases, but were also present in the majority of neurons in 
the middle and deeper cortical layers (Table 1; Fig. 3b, f). 
In keeping with previous descriptions of C9orf72 expansion 
cases ubiquilin-2 inclusions were found in both cerebellum 
and hippocampus (Fig. 3c, g). Further, we investigated the 
presence of dipeptides derived from the unconventional 
translation of the hexanucleotide repeat and found these to 
be present in hippocampal and cerebellar neurons (Fig. 3d, 
h). In all regions the number of p62-positive NCIs outnum-
bered the TDP-43 pathology. The p62 and TDP43 pathol-
ogy was compared to five C9orf72 heterozygous cases and 
assessed as severe but within the range of C9orf72 cases 
(Table 1; Fig. 4a).
C9orf72 transcription analysis of C9orf72 isoforms
For quantitative RT-PCR analysis for the three known 
C9orf72 transcripts [9], we extracted RNA from the frontal 
cortex of the proband, three heterozygous C9orf72 FTD 
cases and four pathologically confirmed controls without 
neurodegenerative disease. Results, normalised to β-actin, 
showed a significant reduction to 57 % of transcript variant 
1 (V1) in heterozygous cases versus controls, whereas the 
homozygous case was reduced further to 20 % of control 
expression. Transcript variants 2 and 3 (V2 and V3) also 
showed a reduction in heterozygous cases, although not 
statistically significant, and a further reduction, respec-
tively, to 34 and 45 % in the homozygous case versus con-
trols (Fig. 3b, c). Results were confirmed using GAPDH as 
a second endogenous control.
Discussion
We report the first FTD patient carrying a homozygous 
C9orf72 hexanucleotide repeat expansion. Our finding that 
the clinicopathological features were severe, but within 
the range of reported heterozygous cases, suggests that 
the condition is truly dominant; therefore, we provide evi-
dence in favour of a gain-of-function mechanism. Whilst 
the affected sister with an age of onset of 21 could also 
be potentially homozygous for the C9orf72 expansion, 
it is highly unlikely that the patient’s mother and also the 
father’s son from his second (non-consanguineous) mar-
riage, both with an onset in their 20s, were homozygous. 
These family members were not available for assessment.
We report Southern blotting for detection of C9orf72 
expansions using two different approaches with the probe 
directed towards either the hexanucleotide repeat itself 
(Fig. 2c) or the adjacent genomic region (Fig. 2d). The for-
mer has the advantage of being more sensitive and is able 
to detect a significant amount of somatic mosaicism, whilst 
the latter has the advantage of detecting also the normal 
allele and therefore its absence in the setting of homozy-
gosity. A size shift, possibly due to somatic instability, is 
documented between blood and brain DNA samples, as 
previously reported [5].
Three major C9orf72 transcripts have been described: 
V1, in which the hexanucleotide expansion is in the pro-
moter region, and V2 and V3, in which the expansion lies 
in the first intron and is therefore transcribed [9]. Previous 
analyses in C9orf72 heterozygous cases showed a reduction 
in V1 and V2 [9, 10]. Consistent with these findings, our 
results indicate a reduction of all three transcripts in het-
erozygous cases, with a further reduction in the homozy-
gous case; but importantly, we unequivocally show that 
transcripts derived from expansion-containing alleles are 
present and clearly detectable in the homozygous case. One 
study [9] observed a greater reduction in the V1 isoform 
than V2 and V3. Although our results show that all variants 
are reduced, we nonetheless observe a greater reduction in 
V1 compared to V2 and V3 in the homozygous case.
The pathogenic mechanism of the C9orf72 repeat expan-
sion is unknown and both loss of function (LOF) [10] and 
gain of function [22] have been proposed to play a role. 
Although the two mechanisms are not mutually exclusive, 
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the clinicopathological data along with the expression pro-
file of the case presented here are consistent with a predomi-
nant gain-of-function mechanism. A pure LOF mutation 
would be expected to cause a much more severe clinical 
presentation and pathology in the homozygous state, which 
was not observed in this case. Indeed heterozygous LOF 
mutations in other neurodegenerative diseases present with 
radically different phenotypes when homozygous, whereas 
those associated with a toxic gain of function tend to be 
present with the same clinical syndrome, although in many 
cases with an earlier onset. Examples include heterozygous 
LOF mutations in the progranulin gene (PGRN) causing 
FTD but homozygous mutations causing a lysosomal stor-
age disorder [4, 29]; mutations in GBA causing Parkin-
son’s disease in heterozygosity and Gaucher’s disease in 
homozygosity [1]; and mutations in TREM2 causing Alzhei-
mer’s disease and Nasu–Hakola disease [11, 14]; however, 
homozygous mutations in gain-of-function neurodegenera-
tive diseases such as inherited prion disease (PRNP), ALS 
(SOD1) and Huntington disease (HTT), manifest with severe 
phenotypes, that fall within the range of disease [13, 15, 28, 
30]. Further, a severe form of disease, but with no additional 
clinical features, such as presented here, was described for 
homozygous cases of myotonic dystrophy types 1 and 2 
(DM1 and DM2) [2, 27]. Importantly, these disorders are 
similar to c9FTD in that they are also caused by very long 
expansions of non-coding repeats, and functional evidence 
suggests they occur via a gain-of-function mechanism [7]. 
The severe pathology here reported in the C9orf72 homozy-
gous case could be compatible with a dosage dependence of 
the GOF mechanism. Gain and loss of function have been 
shown to coexist in other neurodegenerative disorders [8, 
18, 31, 32]. Given the decreased levels of all C9orf72 tran-
scripts, further work is needed to assess the possible role of 
loss of function in C9orf72 ALS/FTD, but our results argue 
against a pure loss-of-function mechanism.
Lastly, C9orf72 is estimated to have a frequency of 
1:700 in the UK population [5], thus making the predicted 
frequency of homozygous cases to be approximately 
1:2 × 106. Although we present a single case and clinical 
variability is likely to occur, our results show that homozy-
gous C9orf72 expansion is viable and that it can present as 
typical FTD. Genetic diagnostic tests are already available 
for C9orf72 and are carried out by performing both repeat-
primed PCR and Southern blotting. Our results underline 
the importance of performing Southern blots in the diag-
nostic test, in order to detect potential homozygous cases. 
Although homozygosity may or may not have prognostic 
Fig. 3  Immunohistochemical analysis of the neuronal cytoplasmic 
inclusions in the C9orf72 homozygous case. The ‘star-like’ neuronal 
cytoplasmic inclusions observed in the granule cell layer of the hip-
pocampus (a–d) and the cerebellum (e–h) have been shown to be 
positive to varying degrees with several antibodies to proteins shown 
to be associated with C9orf72 cases. TDP-43 immunohistochem-
istry showed compact neuronal cytoplasmic inclusions (a arrows) 
together with the normal neuronal nuclear staining pattern. Only 
the normal nuclear staining pattern was observed in the cerebellum 
with the TDP-43 antibody (e). p62 immunohistochemisty (b and f) 
demonstrated large numbers of ‘star-like’ inclusions in both the GCL 
(b) and cerebellum (f). Ubiquilin-2 has been shown to be present in 
the small ‘star-like’ inclusions in heterozygous C9orf72 cases. The 
homozygous presented here also demonstrated a similar staining pat-
tern with inclusions found in the GCL (c) and cerebellum (g). The 
newly identified C9RANT protein was also shown to be present in 
a small proportion of inclusions in the GCL (d) and cerebellum (h 
arrows). Bar in a represents 20 μm in all panels
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implications, it carries huge implications for genetic 
counselling. In summary, we provide the first report of a 
homozygous C9orf72 repeat expansion FTD case, which 
provides new insight into disease pathogenesis and impor-
tant implications for genetic testing.
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